333 related articles for article (PubMed ID: 32933997)
1. Chloroquine Sensitizes
Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
[TBL] [Abstract][Full Text] [Related]
2. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
3. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
[TBL] [Abstract][Full Text] [Related]
4. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
5. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
[TBL] [Abstract][Full Text] [Related]
6. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
7. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
[TBL] [Abstract][Full Text] [Related]
8. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
[TBL] [Abstract][Full Text] [Related]
9. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
[TBL] [Abstract][Full Text] [Related]
12. Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for
Paradis JS; Acosta M; Saddawi-Konefka R; Kishore A; Gomes F; Arang N; Tiago M; Coma S; Lubrano S; Wu X; Ford K; Day CP; Merlino G; Mali P; Pachter JA; Sato T; Aplin AE; Gutkind JS
Clin Cancer Res; 2021 Jun; 27(11):3190-3200. PubMed ID: 33568347
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.
Teh JLF; Purwin TJ; Han A; Chua V; Patel P; Baqai U; Liao C; Bechtel N; Sato T; Davies MA; Aguirre-Ghiso J; Aplin AE
Mol Cancer Ther; 2020 Aug; 19(8):1719-1726. PubMed ID: 32430489
[TBL] [Abstract][Full Text] [Related]
14. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
[TBL] [Abstract][Full Text] [Related]
16. Mutations in GNA11 in uveal melanoma.
Van Raamsdonk CD; Griewank KG; Crosby MB; Garrido MC; Vemula S; Wiesner T; Obenauf AC; Wackernagel W; Green G; Bouvier N; Sozen MM; Baimukanova G; Roy R; Heguy A; Dolgalev I; Khanin R; Busam K; Speicher MR; O'Brien J; Bastian BC
N Engl J Med; 2010 Dec; 363(23):2191-9. PubMed ID: 21083380
[TBL] [Abstract][Full Text] [Related]
17. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
[TBL] [Abstract][Full Text] [Related]
18. Trametinib Induces the Stabilization of a Dual
Krebs FS; Gérard C; Wicky A; Aedo-Lopez V; Missiaglia E; Bisig B; Trimech M; Michielin O; Homicsko K; Zoete V
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126538
[TBL] [Abstract][Full Text] [Related]
19. The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.
Li Y; He J; Qiu C; Shang Q; Qian G; Fan X; Ge S; Jia R
J Cell Biochem; 2019 Apr; 120(4):5766-5776. PubMed ID: 30320917
[TBL] [Abstract][Full Text] [Related]
20. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]